Biblio Discovery — Demo Discovery Service

10 results for "Eric Lefebvre"

Showing 1–10 · 0.67 seconds · RSS

  1. Journal Article Full text

    Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

    Tobias Puengel; Oliver Krenkel; Marlene Kohlhepp et al.

    PLOS ONE, Vol. 12 No. 9 · 2017 · English · PLOS Scopus

    A hallmark of acute hepatic injury is the recruitment of neutrophils, monocytes and lymphocytes, including natural killer (NK) or T cells, towards areas of inflammation. The recruitment of leukocytes from their reservoirs bone marrow or spleen into the liver is directed by chemokines such as CCL2…

    Also available at: DOAJ

  2. Journal Article

    APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz

    Daniela A. Covino; Cristina Purificato; Laura Catapano et al.

    Frontiers in Immunology, Vol. 9 · 2018 · English · DOAJ Scopus

    Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) family members are cytidine deaminases that play crucial roles in innate responses to retrovirus infection. The mechanisms by which some of these enzymes restrict human immunodeficiency virus type 1 (HIV-1) replication have…

  3. Journal Article Full text

    Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates

    Benoit Visseaux; Charlotte Charpentier; Gilles Collin et al.

    PLOS ONE, Vol. 10 No. 8 · 2015 · English · PLOS Scopus

    Background: Maraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of this study was to assess HIV-2 susceptibility to cenicriviroc, a novel, once-daily, dual CCR5 and CCR2 antagonist that has completed Phase 2b…

    Also available at: DOAJ

  4. Journal Article Full text

    Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

    Eric Lefebvre; Graeme Moyle; Ran Reshef et al.

    PLOS ONE, Vol. 11 No. 6 · 2016 · English · PLOS Scopus

    Background & Aims: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an…

    Also available at: DOAJ

  5. Journal Article

    Chronic alcohol-induced neuroinflammation involves CCR2/5-dependent peripheral macrophage infiltration and microglia alterations

    Patrick P. Lowe; Caroline Morel; Aditya Ambade et al.

    Journal of Neuroinflammation, Vol. 17 No. 1 · 2020 · English · DOAJ Scopus

    Abstract Background Chronic alcohol consumption is associated with neuroinflammation, neuronal damage, and behavioral alterations including addiction. Alcohol-induced neuroinflammation is characterized by increased expression of proinflammatory cytokines (including TNFα, IL-1β, and CCL2) and…

  6. Journal Article

    Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study

    Bertus Eksteen; Christopher L. Bowlus; Aldo J. Montano‐Loza et al.

    Hepatology Communications, Vol. 5 No. 3 · 2021 · English · DOAJ Scopus

    Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease with no approved treatments. C‐C chemokine receptor types 2 and 5 (CCR2/CCR5) play an important role in inflammation and fibrosis and are potential therapeutic targets for PSC. We evaluated the efficacy and safety of cenicriviroc…

  7. Journal Article

    The Critical Role of Chemokine (C–C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis

    Debby Reuveni; Yael Gore; Patrick S. C. Leung et al.

    Frontiers in Immunology, Vol. 9 · 2018 · English · DOAJ Scopus

    The therapy of primary biliary cholangitis (PBC) has lagged behind other autoimmune diseases despite significant improvements in our understanding of both immunological and molecular events that lead to loss of tolerance to the E2 component of pyruvate dehydrogenase, the immunodominant autoepitope…